DALLAS, TX / ACCESSWIRE / April 30, 2018 / Puration, Inc. (OTC PINK: PURA) previously announced finalizing terms to complete an acquisition establishing a recreational marijuana grow operation in Canada with a target closing date by May 30th, 2018:

Puration Finalizes Acquisition Terms With Canadian Cannabis Cultivation Operator and Targets May 30th Closing Date

Today the company updates the target closing date indicating the closing is imminent and could be completed by the end of this week. In anticipation of the accelerated closing date, the company has scheduled an online shareholder update for next Thursday, May 10th, to provide details on the acquisition anticipated to be closed by that time.

For more information on Puration, visit http://www.aciconglomerated.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
+1-800-861-1350

SOURCE: Puration, Inc.

ReleaseID: 498015

Annual Best Of New England Summer Travel Guide Offers Inspiration For Ultimate Summer Getaways From Those Who Know The Region Best

DUBLIN, NH / ACCESSWIRE / April 30, 2018 / From Cape Cod to the White Mountains to the Maine coast, Yankee’s annual Best of New England summer travel guide (May/June 2018) is filled with inspiration for the ultimate New England summer getaway. With more than 200 recommendations from the experts at Yankee, the issue is chock-full of the best dining, lodging, and attractions in every New England state. Plus, the editors share their picks for epic outdoor adventures, must-try ice cream flavors, road food that’s worth a detour, the hottest summer events, great dog-friendly overnights, and more.

“This special travel issue of Yankee encourages you to follow your curiosity, to discover side roads, unexpected delight, new places,” writes editor Mel Allen. “What these pages hold are the conversations we editors have after returning from our own outings, and our talks with trusted travel writers who know the nooks and crannies of their home territories.”

Best of New England coverage includes Yankee’s annual selections for the very best dining, lodging, and attractions in every state, from farmers’ markets and family adventures to seafood shacks and luxury hotels.

Readers of the issue, which hits newsstands by May 1, will immediately recognize the popular husband and wife design team of Kiel James Patrick and Sarah Vickers on the cover. The Instagram stars and New England style icons produced and star in the photo, which was taken at Jamestown, Rhode Island’s scenic Mackerel Cove.

“We couldn’t have chosen a better cover image for Yankee’s summer travel issue,” said Lori Pedrick, Yankee’s art director. “It evokes two of the biggest reasons that millions travel to New England every year: road trips and summers by the sea. The image perfectly reflects the fun we hope Yankee readers will have as we steer them to the best of New England travel inside the issue.”

For more information about Yankee, please visit:
https://newengland.com/yankee-magazine/

Based in Dublin, New Hampshire, Yankee: New England’s Magazine is the iconic American magazine covering the finest that New England has to offer. Covering classic New England travel destinations, food traditions, and home and lifestyle stories with stunning photography and artwork, Yankee has featured many notable American writers in its pages such as Robert Frost, John Updike, and Stephen King. Yankee has also recently partnered with WGBH to produce Weekends with Yankee, a 13-episode public television series that taps into Yankee’s extensive behind-the-scenes access to the region’s six states.

SOURCE: Yankee: New England’s Magazine

ReleaseID: 498013

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Foot Locker, Inc. (“Foot Locker”) (NYSE: FL)and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Foot Locker securities between August 19, 2016 and August 17, 2017,both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/fl.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The complaint alleges that throughout the class period, defendants made false and misleading statements and/or failed to disclose to investors that: (1)Foot Locker’s vendors were transitioning to selling through various online retailers, diminishing the utility of Foot Locker’s large number of brick and mortar stores and the once-high value of its exclusivity relationships with those vendors; (2) competition with online retailers had increased the pricing competition Foot Locker faced while also materially lowering the demand at Foot Locker stores; and (3) as a result of defendants’ failure to disclose this information, Foot Locker stock was artificially inflated to a high of $79.20 per share during the Class Period, while executives were able to sell over 192,000 shares of their personally held Foot Locker stock at artificially inflated prices for gross proceeds of $13.3 million.

On August 18, 2017, Foot Locker revealed poor second quarter 2017 financial results, and a 6% drop in quarterly same-store sales year-over-year, causing the substantial revenue miss. Foot Locker announced that it would close roughly 130 stores, more than the 100 stores it had previously announced it would close and on a conference call with investors and analysts that morning, Foot Locker said it expected weaker sales for the remainder of fiscal 2017. Following this news, Foot Locker stock dropped roughly 28% to close at $34.38 per share on August 18, 2017, on unusually high trading volume of more than 36.2 million shares traded.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/fl or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Foot Locker you have until May 8, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 497939

Klis to also speak May 9 at the Beijing EB-5 Expo

NEW YORK, NY / ACCESSWIRE / April 30, 2018 / Polsinelli’s Dan Flanigan, Office Managing Partner of the firm’s New York office, and Debbie Klis, EB-5 Program – Fund, Real Estate and Investor Services co-practice chair, will represent the firm’s Real Estate and Financial Services Department this May as speakers at two major global industry conferences in Beijing.

Polsinelli is also sponsoring these events, as the firm continues to expand its services for international clients, including cross-border transactions with a specialized focus on Chinese investments into the U.S.

Flanigan, who is the founder and chair emeritus of Polsinelli’s Real Estate & Financial Services Department, will moderate a panel titled, “A Guide to Emerging Asset Classes,” and Klis will participate as a panelist in a panel titled, “A Look Into the Future – From Political Events, to Private Funds to Trade Wars,” on Tuesday, May 8, at the 2018 Uglobal Investment Opportunities Forum at the Rosewood Hotel in Beijing. Uglobal, formerly The China Investor, focuses on connecting Chinese financial institutions and institutional investors to global real estate opportunities and facilitating connections between industry professionals to strengthen overseas partnerships.

“We continue to see a great deal of real estate development opportunities in the U.S. by Chinese and other foreign developers and investors, and these events in Beijing offer valuable forums to share our broad and deep experience in navigating cross-border and other development, financial, and M&A transactions throughout our 20 major offices in the U.S.,” Flanigan said.

“Areas where we are seeing particularly interesting opportunities for Chinese investors and developers, include multifamily housing – especially niche areas like manufactured, workforce and student housing – data centers, industrial, senior living, medical offices and other health care real estate,” Flanigan added. “And, for several years now at these conferences I have been emphasizing the opportunities not just in the gateway cities but in the secondary and tertiary markets, all of which we know very well.”

While in Beijing, Klis, who specializes in structuring joint ventures and other investment funds, will also participate as a moderator of a panel titled, “Regional Center and Project Trends,” at the 2018 Beijing EB-5 Expo on Wednesday, May 9. Hosted by eb5 investors Magazine, which recently named Klis among the Top 15 Corporate Attorneys in its EB-5 attorney rankings, the EB-5 Expo includes interactive panels moderated by professionals experienced in the EB-5 Immigrant Investor Program as well as global investment immigration programs.

“Some of the largest new projects in the U.S. are being solely developed by Chinese companies, and they are relying upon EB-5 capital to complete their capital structure,” Klis said. “Whether investors serve as a co-developer with the U.S. developer in the lead, or as the sole or lead developer, we can assist principals and developers with services, including the formation of regional centers or by joining with an existing EB-5 approved regional center through a rental model or arm’s length investment,” she noted.

Polsinelli’s 20 major U.S. offices include Atlanta, Boston, Chicago, Dallas, Denver, Houston, Kansas City, Los Angeles, Nashville, New York, Phoenix, San Francisco, Silicon Valley, St. Louis, Washington, D.C. and Wilmington.

About Polsinelli

Polsinelli is an Am Law 100 firm with more than 800 attorneys in 20 offices. Ranked #24 for Client Service Excellence1 and #10 for best client relationships2 among 650 U.S. law firms, Polsinelli was also named among the top 20 best-known firms in the nation3. The firm’s attorneys provide value through practical legal counsel infused with business insight, and focus on health care, financial services, real estate, intellectual property, mid-market corporate, labor and employment, and business litigation. www.polsinelli.com | Polsinelli PC | In California, Polsinelli LLP

12018 BTI Client Service A-Team Report
22017 BTI Industry Power Rankings
32017 BTI Brand Elite

For more information, contact:

Cathy Loos at cathy@adam-friedman.com, 347-334-4135
Carrie Trent at ctrent@polsinelli.com, 314-552-6854

SOURCE: Polsinelli

ReleaseID: 498010

SAN DIEGO, CA / ACCESSWIRE / April 30, 2018 / Emerald Health Pharmaceuticals, Inc. (EHP), which is developing medicines based on cannabinoid science, announced today that Dr. Jim DeMesa, CEO, will participate in a panel to discuss how disease modifying treatments may alter the course of movement disorders associated with neurodegenerative diseases at the NeuroTech Investing and Partnering Conference. The conference will take place on Wednesday, May 2st, 2018 and is being held at the Renaissance Waterfront Hotel in Boston, MA.

Panel: Parkinson’s & Other Movement Disorders

10:40 AM ET

About Emerald Health Pharmaceuticals Inc.

EHP is developing synthetic cannabinoid-derived drugs for CNS, autoimmune, and other diseases. The company has two families of patented new chemical entities, derived from cannabidiol (CBD) and cannabigerol (CBG), that have been modified through rational drug design to affect pertinent disease-related targets, including peroxisome proliferator-activated receptor-gamma (PPARγ), cannabinoid receptor type 2 (CB2), and the hypoxia inducible factor (HIF) pathway, all of which have been validated through decades of published research. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. The company is completing preclinical development for EHP-101 with the intent to launch a Phase 1 clinical study in 2018.

For more information, visit www.emeraldpharma.life or contact: info@emeraldpharma.life.

Contact

Investor Relations:
Phone: (800) 268-0719

Forward-Looking Statements

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the Private Securities Litigation Reform Act of 1995, that reflect management’s current beliefs[1]and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in this news release include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; and (iv) our ability to raise capital. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA. The Offering Circular is available via this link.

SOURCE: Emerald Health Pharmaceuticals, Inc.

ReleaseID: 498011

RADNOR, PA / ACCESSWIRE / April 30, 2018 / The law firm of Kessler Topaz Meltzer & Check, LLP reminds Solid Biosciences, Inc. (NASDAQ: SLDB) (“Solid Biosciences” or the “Company”) shareholders that a class action lawsuit has been filed against Solid Biosciences on behalf of purchasers of the Company’s securities between January 25, 2018 and March 14, 2018, inclusive (the “Class Period”).

REMINDER: Investors who purchased Solid Biosciences securities during the Class Period may, no later than May 29, 2018, seek to be appointed as a lead plaintiff representative of the class. For additional information or to learn how to participate in this action please visit https://www.ktmc.com/new-cases/solid-biosciences-inc#join.

According to the complaint, Solid Biosciences operates as a biotechnology company. The Company’s lead product candidate, SGT-001, is a gene therapy designed and developed for its potential to help restore functional dystrophin protein expression in patients’ muscles.

According to the complaint, on or about January 25, 2018, Solid Biosciences completed an initial public offering (“IPO”) of common stock, selling over 8.9 million shares of stock to investors at $16.00 per share for gross proceeds of over $143 million.

Then, on March 14, 2018, Solid Biosciences disclosed that the U.S. Food and Drug Administration (“FDA”) had placed a clinical hold on the Company’s SGT-001 Phase I/II clinical trial. The FDA’s clinical hold was imposed in response to a report made to the FDA of a “Suspected Unexpected Serious Adverse Reaction” occurring in the “first patient dosed in the clinical trial.”

Following this news, shares of the Company’s stock declined $16.99 per share, or nearly 65%, to close on March 15, 2018 at $9.32.

Among other things, the shareholder class action complaint alleges that Solid Biosciences’ IPO documents were negligently prepared, contained untrue statements of material fact, and were not prepared in accordance with the rules and regulations governing their preparation. Specifically, the complaint alleges that the Company’s IPO documents failed to disclose: (i) that Solid Biosciences’ lead drug candidate SGT-001 had a high likelihood of causing adverse events in patients; and (ii) that Solid Biosciences misled investors regarding the toxicity of SGT-001.

Shareholders who wish to discuss this action and their legal options are encouraged to contact Kessler Topaz Meltzer & Check, LLP (James Maro, Jr., Esq. or Adrienne Bell, Esq.) at (888) 299-7706 or at info@ktmc.com.

Solid Biosciences shareholders may, no later than May 29, 2018, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. In order to be appointed as a lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members and that the class member will adequately represent the class in the action. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check prosecutes class actions in state and federal courts throughout the country. Kessler Topaz Meltzer & Check is a driving force behind corporate governance reform and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers, and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). The complaint in this action was not filed by Kessler Topaz Meltzer & Check. For more information about Kessler Topaz Meltzer & Check, please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
James Maro, Jr., Esq.
Adrienne Bell, Esq.
280 King of Prussia Road
Radnor, PA 19087
(888) 299-7706
(610) 667-7706
info@ktmc.com

SOURCE: Kessler Topaz Meltzer & Check, LLP

ReleaseID: 497171

MIAMI, FL / ACCESSWIRE / April 30, 2018 / Qrons Inc., (www.Qrons.com) (OTC PINK: QRON) a preclinical biotechnology company that is developing advanced cell-based solutions to combat neurological injuries today announced that it has engaged American Capital Ventures (“ACV”), a boutique provider of comprehensive investor relations services to micro- and small-cap companies, to provide investor relations services to the company.

Jonah Meer, CEO of Qrons Inc, stated, “We are very pleased to announce that we have engaged American Capital Ventures to assist us in strategically presenting our company to the investment community. After interviewing several firms we felt that ACV brings the experience and knowledge we were looking for.” Howard Gostfrand, President of American Capital Ventures, commented, “We are equally as pleased to be working with Qrons Inc. on their investor relations program. The Company has secured a license from a prominent Israeli University and is working closely with Dartmouth College on a research study. We look forward to working alongside management in educating their current and new shareholders on these and future initiatives.”

About Qrons, Inc.

Headquartered in Miami, Florida, the Company is a publicly traded preclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology could potentially treat a wide range of neurodegenerative diseases. The Company’s treatment integrates proprietary, engineered mesenchymal stem cells 3D printable scaffolding, smart materials, and a novel delivery system. The Company entered into a license and research funding agreement (“License Agreement”) with Ariel University R&D Co., Ltd., a wholly owned subsidiary of Ariel University, based in Ariel, Israel. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty-bearing license in Ariel patents and know-how to develop and commercialize products for neuronal tissue regeneration and/or repair, resulting from Ariel’s research or technology or the Company’s research funding. The Company is also conducting a research study with Professor Chenfeng Ke of the Chemistry Department at Dartmouth College aiming to develop innovative 3D printable, biocompatible advanced materials and stem cell delivery techniques to treat TBI. The Company is negotiating, a worldwide, royalty‑bearing, exclusive license for Professor Ke’s 3D printable materials in the field of human and animal health. Please visit http://www.qrons.com.

Safe Harbor Statement

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning our future product development plans, other statements regarding future research, and any other statements which are other than statements of historical fact. These statements involve risks, uncertainties, and assumptions that could cause the Company’s actual operations, results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. The Company has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are the Company’s need for, and the availability of, substantial capital in the future to fund its operations and research and development; successful development of clinical studies for any product we may develop, U.S. Food and Drug Administration clearance for any products developed, manufacturing of a commercially-viable version of our system and demonstration of safety and effectiveness sufficient to generate commercial orders by customers for any product we may develop. A more complete description of these risk factors is included in the Company’s filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. The Company undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:

American Capital Ventures
Howard Gostfrand, President
info@amcapventures.com
+1-305.918.7000

SOURCE: Qrons Inc.

ReleaseID: 497899